HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Prager, M. D. Articles by Bachynsky, N. Search for Related Content PubMed Articles by Prager, M. D. Articles by Bachynsky, N.

Immunity to the 6C3HED Ascites Tumor Following Treatment of Tumor-Bearing Mice with Escherichia coli L-Asparaginase¹

Wadley Research Institute and Blood Bank and the Graduate Research Institute of Baylor University, Dallas, Texas

Abstract

Long-lived immunity to the 6C3HED ascites lymphosarcoma in C3H/HE mice following treatment of the tumor-bearing animals with Escherichia coli L-asparaginase has been observed. This tumor which had its origin in C3H mice is normally lethal for this strain. Immunity of C3H/HE mice was demonstrated by (1) tumor rejection, (2) neutralization of tumor cells by immune serum and lymphoid extract, and (3) in vitro cytotoxicity of the same preparations. Adsorption experiments with normal C3H/HE lymphatic cells and 6C3HED-OG tumor cells indicate that the immune response in C3H/HE mice is directed against an antigen unique for the tumor cells. This point was underscored by the decrease in cytotoxicity and neutralizing activity of immune C57BL serum following adsorption with normal C3H/HE lymphatic cells. In these mice the immune response was directed primarily against histoincompatibility antigens. When tumor-bearing C3H/HE mice were treated with 6-mercaptopurine and asparaginase, the primary immune response was blocked, and the mice were unable to reject a subsequent implant of 6C3HED cells. C3H/HE mice rendered immune to the 6C3HED-OG tumor following asparaginase therapy were also immune to the asparaginase-resistant 6C3HED-RG1 lymphosarcoma.

Footnotes

¹ Aided in part by a gift from the Dallas alumnⁱ of Sigma Delta Tau sorority.

² This work was taken from a thesis submitted to the faculty of the Graduate Research Institute of Baylor University in partial fulfillment of the requirements for the M.S. degree.

This article has been cited by other articles:

				J. M. Hill, J. Roberts, E. Loeb, A. Khan, A. MacLellan, and R. W. Hill L-Asparaginase Therapy for Leukemia and Other Malignant Neoplasms: Remission in Human Leukemia JAMA, November 27, 1967; 202(9): 882 - 888. [Abstract] [PDF]